Alpha-1 receptor subtypes decide whether one drug can treat an enlarged prostate and high pressure together; the NU559 Unit 8 analysis weighs that question for a composite organist in his late sixties. Searches like "nu 559 unit 8 assignment example", "nu559 unit 8 sample" and "nu559 unit 8 example" land here.
One Pill for Two Problems? Alpha-1 Blockade, an Enlarged Prostate and Blood Pressure in a 68-Year-Old Organist
[Student Name]
Purdue University Global
NU559: Essentials of Advanced Pathophysiology and Pharmacology
Unit 8 Comorbidity Analysis
[Instructor Name]
[Date]
The patient is a composite; agents in brackets stand for their classes, and values are illustrative.
The Request
Mr. [C.], 68, has played the organ at his church for forty years. He gets up three times a night to urinate, his stream is weak, and he sometimes feels he has not emptied his bladder. An examination and urinalysis are consistent with benign prostatic enlargement. His blood pressure averages [148/90] mm Hg on [lisinopril]. He has read that one drug can treat both conditions and asks whether he could take a single pill instead of adding two.
The request is reasonable, and the mechanism permits it. Whether it is wise depends on what the drug does to each condition, including the one it was not chosen for.
The Receptors
Alpha-1 adrenergic receptors respond to norepinephrine by contracting smooth muscle. Three subtypes matter here. Alpha-1A receptors predominate in the smooth muscle of the prostate and bladder neck, where their contraction narrows the urethra. Alpha-1B receptors are prominent in vascular smooth muscle, where their contraction constricts arterioles and raises blood pressure. Alpha-1D receptors are found in the bladder and spinal cord and also in some vessels. Blocking alpha-1A receptors relaxes the prostate and eases flow; blocking alpha-1B receptors relaxes arterioles and lowers pressure.
The Grid
1. [Doxazosin], on the enlarged prostate. Blocks alpha-1 receptors of all subtypes, including alpha-1A in the prostate. Effect: relaxes prostate smooth muscle, improves flow and reduces nighttime urination. Benefit.
2. [Doxazosin], on hypertension. Blocks alpha-1B receptors in arterioles. Effect: lowers peripheral resistance and blood pressure. Apparent benefit, with a cost: dizziness and falls on standing, especially after the first dose.
3. [Tamsulosin], on the enlarged prostate. Favors the alpha-1A subtype. Effect: relaxes prostate smooth muscle and improves flow with little change in pressure. Benefit.
4. [Tamsulosin], on hypertension. Little effect on alpha-1B receptors in arterioles. Effect: minimal change in pressure. It will not treat the hypertension and is not expected to.
Explaining Each Cell
[Doxazosin] and the prostate. The drug blocks the receptors that keep the prostate's smooth muscle contracted, so the urethra widens and flow improves within days to weeks. The AUA guideline lists alpha blockers as a first-line option for bothersome urinary symptoms from prostatic enlargement (Lerner et al., 2021).
[Doxazosin] and blood pressure. The same drug relaxes arterioles, which lowers his pressure. On mechanism alone, it would treat both conditions. But the outcome evidence tells a different story. In ALLHAT, a very large trial comparing first-line antihypertensive drugs, the doxazosin arm was stopped early because participants taking it had more cardiovascular events, particularly heart failure, than those taking [chlorthalidone] (ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, 2000). Doxazosin lowers pressure, but it does not appear to protect against the outcomes that blood pressure treatment is meant to prevent as well as other classes do. That is why alpha blockers are not recommended as first-line treatment for hypertension, and why the one-pill idea is set aside for his pressure even though the mechanism permits it.
Doxazosin also carries the first-dose effect: blocking alpha-1B receptors in veins and arterioles can cause a sharp fall in pressure on standing, with dizziness or fainting, especially after the first dose or a dose increase. For a man who climbs to an organ loft and gets up three times a night in the dark, that risk matters.
[Tamsulosin] and the prostate. It relaxes prostate smooth muscle as effectively as doxazosin for most men, because the alpha-1A subtype it favors is the one that governs prostate tone (Lerner et al., 2021).
[Tamsulosin] and blood pressure. Because it spares alpha-1B receptors in arterioles relatively, it has less effect on pressure and causes less dizziness. It will not treat his hypertension, and that is expected. His pressure needs a separate decision.
What Each Condition Does to the Other's Treatment
Treating the prostate could affect his pressure. Adding doxazosin to lisinopril would lower pressure further, perhaps too far on standing. Tamsulosin would add little.
Treating his pressure could affect his urinary symptoms. A thiazide diuretic, a reasonable next step for his hypertension, increases urine volume and, if taken late in the day, could worsen nighttime urination. A dihydropyridine calcium channel blocker would not affect urination, though it can cause ankle swelling. Increasing lisinopril is another option with no effect on the prostate.
Getting Up at Night Has More Than One Cause
Before any drug is chosen for the prostate, his nighttime urination deserves its own look, because the prostate may not be the only cause. A frequency-volume chart kept for three days would show whether he passes large volumes overnight, which points to nocturnal polyuria rather than obstruction. Evening fluids and coffee after choir practice, ankle swelling that is reabsorbed when he lies down, untreated sleep apnea and poorly controlled blood glucose can each add trips to the bathroom that no alpha blocker will remove. If the chart shows large overnight volumes, moving fluids earlier in the day and reviewing his other conditions may help as much as a prostate drug. If it shows small, frequent voids with a weak stream, the prostate is the main driver and the grid above applies.
The Cataract Operation
One more detail changes the calculation. Mr. [C.] has a cataract operation scheduled in three months. The muscle that dilates the pupil, the iris dilator, is supplied by alpha-1A receptors. Blocking them can cause intraoperative floppy iris syndrome, in which the iris billows, the pupil constricts during surgery and complications become more likely. The syndrome was first described in patients taking tamsulosin (Chang & Campbell, 2005), which is the prediction from its alpha-1A selectivity, and it can occur with other alpha blockers as well. The effect can persist even after the drug is stopped.
The surgeon must know about any alpha blocker he takes, even one taken briefly. Some clinicians would delay starting an alpha blocker until after the operation, or choose a 5-alpha reductase inhibitor for longer-term prostate treatment, though that class takes months to shrink the prostate.
Conclusion
The single pill is not the better choice. For his pressure, the outcome evidence favors increasing lisinopril or adding a dihydropyridine calcium channel blocker. For his prostate, tamsulosin is effective with less effect on pressure, but its timing relative to the cataract operation is a decision to make with the surgeon. Consideration for the prescriber: [defer the alpha blocker until after cataract surgery, or start it with the ophthalmologist informed].
References
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2000). Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 283(15), 1967-1975. https://doi.org/10.1001/jama.283.15.1967
Chang, D. F., & Campbell, J. R. (2005). Intraoperative floppy iris syndrome associated with tamsulosin. Journal of Cataract and Refractive Surgery, 31(4), 664-673. https://doi.org/10.1016/j.jcrs.2005.02.027
Lerner, L. B., McVary, K. T., Barry, M. J., Bixler, B. R., Dahm, P., Das, A. K., Gandhi, M. C., Kaplan, S. A., Kohler, T. S., Martin, L., Parsons, J. K., Roehrborn, C. G., Stoffel, J. T., Welliver, C., & Wilt, T. J. (2021). Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. Journal of Urology, 206(4), 806-817. https://doi.org/10.1097/JU.0000000000002183
How this NU559 Unit 8 example is structured
The analysis runs in both directions, which is what distinguishes a comorbidity paper from a drug profile. For each candidate it asks what the drug does to the target condition and then what it does to the other condition, benefit or harm. Receptor subtype distribution carries the argument: alpha-1A in the prostate, alpha-1B in vascular smooth muscle, alpha-1D in the bladder and elsewhere. The hypertension side then turns to outcome evidence, citing the doxazosin arm of ALLHAT, stopped early in 2000 because heart failure occurred more often than with chlorthalidone, so the one-pill idea is set aside for pressure even though the mechanism permits it. The cataract detail brings in intraoperative floppy iris syndrome, first described with tamsulosin in 2005, as a prediction from alpha-1A receptors in the iris dilator muscle. A bracketed consideration for the prescriber closes the paper.
Get an NU559 Unit 8 example written to your instructions
Comorbidity prompts pair many conditions, so give the two your NU559 Unit 8 case combines, the medication list if one is supplied and the rubric. The sample grid weighs each option in both directions, with receptor locations shown and every agent bracketed. Expect it within 24-48h; nothing is charged the first time. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU559 Unit 8 questions, answered
Must the analysis consider more than two drugs?
Not usually. Two well-chosen candidates, examined in both directions, show the reasoning more clearly than five examined in one. If the prompt asks for all reasonable options, a short table can list the others with a line each while the detailed discussion stays with the pair that best exposes the tension between the two conditions.
How should an old trial like ALLHAT be presented today?
As the evidence it still is, with its year and the specific finding used. The doxazosin arm ended early in 2000, and that result continues to shape how alpha blockers are regarded for pressure. A sentence noting that current hypertension guidance does not list them among first-line agents connects the old trial to present practice without overstating either source.
Where does the patient's own preference fit in a mechanism paper?
Near the end, as a factor the mechanism has to accommodate. A request for one pill is reasonable and deserves an answer explaining why it may not be possible. Recording the preference and responding to it shows the analysis concerns a person, which many rubrics credit, without letting preference override the evidence the paper has already laid out.